PUBLISHER: Allied Market Research | PRODUCT CODE: 1365749
PUBLISHER: Allied Market Research | PRODUCT CODE: 1365749
According to a new report published by Allied Market Research, titled, "Animal Model Market," The animal model market was valued at $1.9 billion in 2022, and is estimated to reach $3.6 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032.
Vaccines are the most effective and economical tools in preventing and controlling infectious diseases. Owing to the rapid spread of SARS-CoV-2, the variability among clinical cases, their outcomes, and high mortality rates, a race to find pharmacological treatments and vaccines was initiated once the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern in January 2020 and a pandemic in March 2020. In context, of vaccine development for COVID-19, the use and choice of reliable and well-characterized experimental models were important for the rapid advancement of research and, consequently, the registration and availability of the vaccines. According to a 2021 report by the National Library of Medicines, animal models involved in the study of COVID-19 include mice, golden hamsters, ferrets, nonhuman primates, and pigs. More than 302 vaccines were under development, of which 117 of them have successfully entered clinical trials. Thus, increase in usage of animal models in the development of vaccines for infectious diseases is expected to contribute significantly in the growth of the market.
Increased adoption of CRISPR (clustered regularly interspaced short palindromic repeats) technology has emerged as a major driver of the animal model market. CRISPR technology allows for precise and efficient genome editing by enabling scientists to make targeted modifications in the DNA of various organisms, including animals. This revolutionary gene-editing tool has significantly advanced the field of genetics and biomedical research, offering numerous applications in the creation of animal models. Furthermore, animal models generated by CRISPR technology have been crucial in the discovery of new medicines. This technology generates highly customized mice and rats whose DNA has been altered to reflect a humanized immune system, which enables precision modeling in research as well as target validation and efficacy assessment. Prior to the use of this technology, it took up to 18 months to produce test animals, whereas now it takes anywhere from one-third to one-half the time to create a founder animal, making it more cost-effective than alternative preclinical animal models. Thus, rise in adoption CRISPR and increase in mouse model-based research are expected to drive the growth of the market. For instance, the U.S. medical and health research and development investment reached $245.1 billion in 2020, an 11.1% increase in 2020. Increase in research activities in the mice model to effectively use them in drug development process is expected to drive the growth of the market. However, ethical guidelines for the use of animals in research are expected to restrain the growth of the animal model market.
The global animal model market is segmented into animal type, application, end user, and region. On the basis of animal type, the market is categorized into rat, mice, guinea pigs, rabbits, and others. The others include zebrafish, amphibians & reptiles, hamsters, chinchillas, gerbils, and armadillo. By application, the market is divided into drug discovery & development, basic research, and others. The others include medical device development, and production & quality control. Depending on end user, the market is segregated into pharma & biotech companies, academic research institutes, and others. The others segment includes medical device companies, contract research organizations (CROs), and contract manufacturing organizations. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
The key players that operate in the global animal model market are The Jackson Laboratory, Janvier Labs, LLC, Genoway S.A., Hera Biolabs, Crown Bioscience Inc, Ozgene Pty Ltd., Taconic Biosciences, Trans Genic Inc., Inotiv, Inc., and Charles River Laboratories.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)